RxDoctor Payments Data

Jamila Battle

Sleep Medicine · Raleigh, NCNPI 1366560872

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Idorsia Pharmaceuticals US Inc at 59.4% of the total. Reporting peaked in 2023 at $7,834 and has fallen 67.4% since, to $2,551 in 2025. Among sleep medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,635in general payments, 2019–2025

Across 73 payments — averaging $173.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$8K
  • Lilly USA, LLC$2K
  • Jazz Pharmaceuticals Inc.$1K
  • Harmony Biosciences LLC$373
  • Axsome Therapeutics, Inc.$234
  • Indivior Inc.$227
  • plus $901 from 10 others
$110,955in research payments, 2019–2025

Across 23 payments — averaging $4824.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$111K

What the payments were for

  • Consulting fees$6,98855%
  • Speaking & faculty fees$2,10017%
  • Travel & lodging$1451%
  • Food & beverage$2,97424%
  • Education$4293%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,635 in reported general payments places this provider in the 90th percentile of 52 sleep medicine providers in North Carolina.

See all sleep medicine providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$4,515
Buprenorphine Hcl13$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Orexo US, Inc.Zubsolv$14$4,51513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 sleep medicine providers in North Carolina.

Other sleep medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →